Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 3/20 | 0.46 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149909 | 0.87 | IDO1 (0.61) | IDO1HRH4HRH3PYGL | |
| SCHEMBL17149821 | 0.85 | KDM4E (0.50) | IDO1PYGLPYGMMEN1KMT2A | |
| SCHEMBL17149836 | 0.85 | KDM4E (0.47) | IDO1NPC1RAB9A | |
| SCHEMBL18750630 | 0.85 | KDM4E (0.58) | HRH4PYGLPYGMMEN1KMT2A | |
| SCHEMBL17149663 | 0.85 | HRH4 (0.50) | IDO1HRH4PYGLPYGM | |
| SCHEMBL17149834 | 0.83 | PDGFRB (0.48) | IDO1MEN1POLBKMT2ANPC1 | |
| SCHEMBL17149825 | 0.82 | KDM4E (0.55) | IDO1KMT2ARAB9A | |
| SCHEMBL17149788 | 0.81 | ALOX15 (0.45) | IDO1NPC1RAB9A | |
| SCHEMBL17149820 | 0.81 | PYGL (0.60) | PYGLMEN1POLBKMT2ABCAT1 | |
| SCHEMBL17149637 | 0.79 | KDM4E (0.55) | PYGLNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | IDO1 1/4885HRH4 67/4885HRH3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.